Pharma Pricing

Dear Reimbursement, Health Outcomes, or Market Access Professional,

If you have signed up for our pharma pricing strategy updates, you are about to receive two comprehensive, professional quality reports on FDA guidelines for new anti-diabetic treatment options. I was so excited by some of the points brought up by my mentor, and long-time pharmaceutical industry opinion leader, Larry Gorkin, that I decided to make a video case study of an FDA mandated phase III trial by Takeda for Alogliptin, which he alerted me to. It hardly does justice to these life sciences commercial strategy reports, but it’s a tiny glimpse of the comprehensive health outcomes analysis available inside.

If you have not signed up for our reimbursement and market access reports, enter your name and email address on the right hand side… Not only will you get these two comprehensive pricing strategy reports on a therapeutic indication with over 25.8 million patients in America alone, you will get access to a myriad of related comprehensive case studies across numerous disease indications, all pertaining to the most relevant and controversial pricing policy decisions and trends. You will be able to effortlessly analyze factors that influence reimbursement decisions by health technology assessment decision makers, on your own schedule, from anywhere. In the interim though, the video below will give you a brief but limited glimpse of what you are missing.

I hope you enjoyed the video. I encourage you to leave a comment. But please excuse my allergies.

My goal here is to be open and accountable. I am eager to improve and engage in constructive discourse. I have been very lucky to be able to collaborate with some incredibly experienced pharma market access, health outcomes, and pricing and reimbursement strategists. I feel compelled to share the competitive knowledge that I acquire in my conversations with titans of life sciences health care policy and pricing strategy.

Note: All figures referenced in full in report.

Incoming search terms:

• fda diabetes guidelines
• market access diabetes
• alogliptin notes fda
• fda diabetes guideline